Objectives: To detect vascular
Introduction
Cervical cancer is the most common gynaecological malignancy in China. 1, 2 Despite advances in multimodal therapeutic modalities, cervical cancer prognosis remain unsatisfactory. [3] [4] [5] The presence of lymph node metastasis has been specifically recognized as an important unfavourable prognostic factor for cervical cancer and a major cause of death. 6 However, even for patients with 'pathologic N0' (pN0) disease, cancer recurrence can develop after potentially curative resection, therefore the prognosis of patients with pN0 can still remain poor. [7] [8] [9] To date, there is no available biomarker routinely used to predict the prognosis of pN0 cervical cancer. Therefore, identifying more specific biomarkers (in order to better stratify individual patients at high risk of recurrence after complete resection of pN0 cervical cancer, and to identify those who will benefit from adjuvant therapy) has become important in the drive to improve clinical outcomes.
Vascular endothelial growth factor (VEGF)-C, which is a member of the VEGF family, regulates the formation of lymphatic systems in both physiological and pathological conditions via its cognate receptor, VEGF receptor-3. 10, 11 As a specific lymphangiogenic factor, VEGF-C expression is upregulated in a variety of human malignancies and is closely correlated with lymphatic metastasis and poor prognosis. 12, 13 However, few studies have evaluated possible clinical roles of VEGF-C in patients with cervical cancer. [14] [15] [16] [17] [18] No data are available regarding VEGF-C mRNA expression and its correlation with lymph node recurrence and prognosis, in patients with surgically resected pN0 cervical cancer.
In the present study, we detected VEGF-C mRNA expression in cases of surgically resected specimens of pN0 cervical cancer by reverse transcriptasepolymerase chain reaction (RT-PCR), analysed the relationship between VEGF-C mRNA expression and clinicopathological factors, lymph node recurrence and prognosis, and further identified the significantly independent predictor for lymph node recurrence and prognosis, in patients undergoing complete resection of pN0 cervical cancer.
Patients and methods

Patients and samples
Patients selected for inclusion in this study had been diagnosed with cervical squamous cell cancer between January 2000 and January 2006 at the Second Hospital of Shandong University; they had undergone radical hysterectomy with bilateral adnexectomy and bilateral pelvic lymphadenectomy (no distant metastasis) without preoperative adjuvant therapy. A total of 78 patients were enrolled sequentially in this retrospective study, with a mean AE SD age of 43 AE 8.1 years (range 31-67 years). Patients who underwent incomplete resection, with regional lymph node metastasis, with a history of other malignancies, those who died of perioperative complications and those lost to follow-up were excluded. All patients provided informed consent to participate in this study and to donate tissue, and a signed consent form was also obtained from each patient before obtaining the tissue. The protocol was approved by the Human Ethics Review Board of the Second Hospital of Shandong University, China.
Histological classification and postoperative pathological staging were determined, based on the classification of the International Federation of Gynecology and Obstetrics (International Federation of Gynecology and Obstetrics Cancer Committee; FIGO, 1995). 19 Tumour tissue blocks $1 cm 3 , wrapped in silver paper, were quickly frozen in liquid nitrogen for $1 min, then stored at À80 C until target mRNA could be detected. Other parts of surgical specimens were histopathologically assessed according to methods described previously. 20, 21 Each cancer tissue was labelled and handled with a set of clean instruments to prevent potential crosscontamination of VEGF-C mRNA. After surgery, each surgical specimen was fixed in formalin and sent for histological examination. The pathologist recorded the size in three dimensions. Lymph node tissues were fixed in 10% formalin, embedded in paraffin wax, and 4mm sections were made for histological evaluation. A standard hematoxylin and eosin (H&E) protocol was used to stain the sections from each tissue slice. Serial sections of each lymph node specimen were meticulously examined by an expert in gynecological pathology to ensure the accuracy of pN0 status for each patient (Z.C.J.)
All histological slides were reviewed by a surgical pathologist. Primary tumours were graded according to the following criteria: well differentiated (grade 1) -neoplastic cells are arranged in nests or sheets, have moderately pleomorphic nuclei and abundant cytoplasm, and display abundant keratinization of individual cells and groups of cells (epithelial pearls); moderately differentiated (grade 2) -The tumour is composed of more pleomorphic cells with less abundant cytoplasm, less keratin, and fewer epithelial pearls; poorly differentiated (grade 3) -there are sheets or cords of cells with very pleomorphic nuclei, relatively little cytoplasm, and isolated foci of keratinization.
RNA extraction and RT-PCR
Total RNA was extracted from 100 mg of each cancer tissue using Trizol Õ reagent (TaKaRa, Tokyo, Japan), according to the manufacturer's instructions. RNA purity and concentration were determined by standard UV spectrophotometric assay. The total RNA of each cancer tissue was reverse-transcribed into cDNA using a BioRT two-step RT-PCR kit (BioER, Hangzhou, China). The following primers were used for amplification of VEGF-C: sense 5 0 -AAGGAGGCTGGCAACATAA C-3 0 ; antisense 5 0 -CCACATCTGTAG-ACGGACAC-3 0 . The primers of VEGF-C yielded a product of 206 base pairs (bp). b-Actin was amplified as an internal control using the following primers: sense 5 0 -ACG TT-ATGGATGATGATATCGC-3 0 ; antisense 5 0 -CTTAATGTCACGCACGAT-TTCC-3 0 . The primers of b-actin yielded a product of 644 bp.
Following an initial denaturation at 94 C for 5 min, the samples were amplified by 30 cycles of denaturation at 94 C for 30 s, annealing at 58 C for 30 s, extension at 72 C for 30 s, and ended by extension at 72 C for 10 min. PCR products were visualized by electrophoresis through 1% agarose gels stained with ethidium bromide. Gel images were obtained using an AlphaImager TM 2200 UV-image analyser (Alpha Innotech, San Leandro, CA, USA).
Follow-up
All patients were routinely examined at 3 -6 monthly intervals for the first 3 years following surgery, and every 6 months thereafter. During each follow-up, the patient underwent a thorough physical examination, laboratory analysis, ultrasonography, computed tomography (CT) scan and positron emission tomography/computed tomography (PET/CT) examination if necessary to detect recurrent disease. Lymph node recurrence was clinically diagnosed when enlarged lymph nodes were detected, compared with the preoperative images. When swollen lymph nodes in cervical or supraclavicular regions were found, patients received ultrasound (US)-guided puncture biopsy through the cervical or supraclavicular approach for pathological diagnosis. The US-guided fine-needle aspiration biopsy was performed using a 21G injection needle, as described in part by Fultz et al. 22 The time and site of postoperative lymph node recurrence were recorded. Follow-up was completed for all 78 patients to the date of death or until 60 months after surgery. Those who survived >60 months after surgery were not routinely followed up thereafter.
Statistical analyses
All statistical analyses were performed with SPSS Õ software, version13.0 (SPSS Inc., Chicago, IL, USA). Correlations of VEGF-C mRNA expression with clinicopathological factors were evaluated using the V 2 -test. Kaplan-Meier analysis was used to calculate the lymph node recurrence and survival curves, and log-rank test was used to compare the statistical significance of differences between the curves of patient subgroups. Cox regression multivariate analysis was performed to identify independent predictors for lymph node recurrence and prognosis. Differences between groups were considered significant at P < 0.05.
Results
Patients and samples
A total of 78 eligible patients were enrolled in this prospective study. The clinical characteristics of these patients are listed in Table 1 .
VEGF-C mRNA expression in cervical cancer tissues
All samples of normal epithelium tissues were negative for VEGF-C DNA, as shown by gel electrophoresis (Figure 1 ). Among the 78 cervical cancer tissues, 35 patients (44.87%) were positive for VEGF-C DNA, and 43 patients (55.13%) were negative. Samples in Lanes 1-2 were taken from normal epithelial tissue; samples in Lanes Table 1 . Baseline clinical characteristics of participants in a study investigating expression of vascular endothelial growth factor (VEGF)-C mRNA in surgically resected tissue samples from women with 'pathologic N0' (pN0) cervical cancer, and correlations between VEGF-C mRNA expression and clinicopathological variables.
Variable
Cases, n 19 3-4 were taken from cervical cancer tissue with negative VEGF-C mRNA expression. The nucleotide sequence of VEGF-C mRNA-positive products confirmed that the 206 bp fragment of cDNA was 100% homologous to the human VEGF-C gene.
VEGF-C mRNA expression and clinicopathological factors
Correlations between VEGF-C mRNA expression and clinicopathological variables are shown in Table 1 . VEGF-C mRNA expression was significantly associated with tumour differentiation (P ¼ 0.008). There were no statistically significant correlations between VEGF-C mRNA expression and age, FIGO stage or tumour length (Table 1) .
VEGF-C mRNA expression and lymph node recurrence
Lymph node recurrence developed in 23 (29.49%) patients within 5 years of surgery. Sites of lymph node recurrence are listed in Table 2 . Lymph node recurrence occurred in 15 of 35 (42.86%) cases with VEGF-C mRNA expression and in eight of 43 cases (18.60%) without VEGF-C mRNA expression (P ¼ 0.019). In addition, univariate analysis demonstrated that the 5-year lymph node recurrence rate for patients with VEGF-C mRNA expression was significantly higher than that for those without VEGF-C mRNA expression (42.86% versus 18.60%, P ¼ 0.017; Figure 2A ). However, no statistically significant correlations with age, FIGO stage, differentiation or tumour length were demonstrated for lymph node recurrence (Table 3 ). Furthermore, multivariate analysis revealed that VEGF-C mRNA expression retained significance as an independent predictor for lymph node recurrence (P ¼ 0.047, 95% CI: 1.012-6.251, Table 3 ).
VEGF-C mRNA expression and prognosis
Of the 78 patients, 17 (21.79%) died within 5 years of surgery; therefore the 5-year overall Figure 2B ). However, no statistically significant correlations with age, FIGO stage, differentiation or tumour length were demonstrated for unfavourable overall survival (Table 3 ). Furthermore, multivariate analysis revealed that VEGF-C mRNA expression retained significance as an independent predictor for unfavourable overall survival (P ¼ 0.020, 95% CI: 1.233À11.577, Table 3 ). 
Discussion
Cervical cancer is the second most common malignant tumour type affecting women worldwide. Despite major advances that have been made in therapeutic approaches, most patients ultimately succumb to cancer progression. [3] [4] [5] 23 Lymph node metastasis has been documented as an important unfavourable prognostic factor and a major cause of cancer-related death. 24 Although the lymph nodes of pN0 disease are histologically negative, lymph node recurrence still can develop after radical surgical resection. 25, 26 Therefore it would be of considerable clinical value if the recurrence risk of patients with pN0 disease after radical resection could be adequately predicted by relevant biomarkers. Lymph node metastasis is a crucial early step in the metastatic process, and angiogenesis has been known to play an important role in the development of tumour growth and lymph node metastasis. 27 The VEGF family is the most widely investigated and most specific regulator of angiogenesis: it consists of six members: VEGF-A, -B, -C, -D, -E and placental growth factor. Among them, VEGF-C and -D are considered to be responsible for tumour lymphangiogenesis and lymph node metastasis. 28 They potently increase vascular permeability and promote the formation of new blood vessels in tumours, and thus are regarded as the main growth stimulatory factors in tumour-related angiogenesis. 29 This function is mediated via VEGF receptor (VEGFR)-3, which is only expressed in the lymphatic vessels and stimulated by the above molecules. VEGF-C has received attention as it is one of the most potent growth factors for inducing lymphangiogenesis and promoting lymph node metastasis in a wide range of human malignant tumours. 18, 27 However, few data are available regarding the correlation between VEGF-C expression and tumour lymph node recurrence. 30 To our knowledge, the present clinical study is the first to detect VEGF-C mRNA expression in surgically resected pN0 cervical cancer tissues, and to investigate further the role of VEGF-C mRNA expression in relation to clinicopathological factors, lymph node recurrence and prognosis of this disease.
Findings of the present study showed that VEGF-C mRNA expression was common in pN0 cervical cancer tissues and was significantly associated with tumour differentiation. In addition, the results of univariate analysis demonstrated that VEGF-C mRNA expression was significantly associated with lymph node recurrence and unfavourable overall survival rates, 5 years after surgery. To eliminate the impact of mixed factors correlated with lymph node recurrence and overall survival on statistical analysis, a Cox regression multivariate analysis was performed to identify independent predictive factors. The results of this confirmed that VEGF-C mRNA expression retained significance as an independent predictor for postoperative lymph node recurrence and unfavourable overall survival.
In conclusion, this study provides evidence that VEGF-C mRNA expression is common in pN0 cervical cancer tissue samples, and is closely correlated with postoperative lymph node recurrence and poor prognosis in this disease. Our findings indicate that VEGF-C may have promising clinical potential for the identification of individuals with pN0 cervical cancer who are at high risk of lymph node recurrence and poor prognosis. The possible association between VEGF-C mRNA expression and therapeutic response warrants further prospective research. VEGF-C mRNA expression may provide predictive information and facilitate enrolment of the subgroup of patients with early stage cervical cancer in postoperative adjuvant therapy, because of their high risk of lymph node recurrence and poor prognosis. Such studies might provide important information that could optimize more personalized therapy for patients with early stage cervical cancer, and improve clinical outcomes.
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